Agency classClass IIOur severity:Severe FDA (Drugs)·D-0819-2026·Announced 2026-09-09

Baxter Recalls Vasopressin Injection Due to Manufacturing Deviations

Baxter Healthcare is voluntarily recalling specific lots of Vasopressin in 0.9% Sodium Chloride Injection due to Current Good Manufacturing Practice (CGMP) deviations.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls involving significant injury/property-damage reports or structural defects are Severe; while no specific injuries are reported in the text, the Class II classification for a sterile IV drug with CGMP deviations warrants a Severe rating as it is not a Class I (Critical) but involves a potential for serious harm.

Plain-English summary

Baxter Healthcare Corporation is voluntarily recalling specific lots of Vasopressin in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dose Container. The recall was initiated on August 6, 2026, and is classified as Class II by the FDA. The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations.

The affected product is distributed in the United States, Puerto Rico, and Chile. The specific lots subject to the recall are Lot # NC185448 (Expiration Date: 8/31/2027), Lot # NC192910 (Expiration Date: 4/30/2028), and Lot # NC195218 (Expiration Date: 6/30/2028). The product is a prescription-only, sterile intravenous injection.

Healthcare providers and patients should check their inventory and medication records for these specific lot numbers. If you have this product, do not use it and contact your healthcare provider or the manufacturer for instructions on how to return or dispose of the medication.

The recalled product

Product: VASOPRESSIN IN 0.9% SODIUM CHLORIDE (VASOPRESSIN IN 0.9% SODIUM CHLORIDE)
Brand: VASOPRESSIN IN 0.9% SODIUM CHLORIDE
Manufacturer: Baxter Healthcare Corporation
Category: Drug — Prescription Injection
Hazard: cgmp-deviation
sterility

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (6)

Lot # NC185448
Exp Date: 8/31/2027
Lot # NC192910
Exp Date: 4/30/2028
Lot # NC195218
Exp Date: 6/30/2028.

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically:

Same brand · VASOPRESSIN IN 0.9% SODIUM CHLORIDE

High
Baxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09

Same manufacturer · Baxter Healthcare Corporation

See all →

High
Baxter Recalls Likorall Overhead Lifts Due to Motor Shaft Breakage Risk
FDA (Devices) · 2026-10-21
Moderate
Baxter Recalls Two VOLARA Systems Due to Potential Flow Rate Inaccuracy
FDA (Devices) · 2026-09-30
Moderate
Baxter PRO+ 36-inch Mattress Recalled for UDI Labeling Error
FDA (Devices) · 2026-09-30
Moderate
Baxter PRO+ Mattress Recalled for UDI Labeling Error
FDA (Devices) · 2026-09-30
Moderate
Baxter Recalls PRO+ MRS Mattress Due to UDI Labeling Error
FDA (Devices) · 2026-09-30

Same hazard · cgmp deviation